Similar to B16-F10 tumors, LLC tumors treated with a combination of anti-PD-1 and anti-PD-L1 displayed significantly reduced tumor growth rate compared to isotype control-treated mice (Figure S1B). This evidence concerns the gene PDCD1 and neoplasm.